BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:VV119 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of VV119\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07703956-9327@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:VV119: Phase 2 readout est. (NCT07703956)
DESCRIPTION:VV119\, phase 2\, Schizophrenia.\nStudy: Evaluating Safety and 
 Efficacy of VV119 in Acute Schizophrenia Adults\nEstimated primary complet
 ion: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /vv119#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07703956
URL:https://assetmemo.bio/drug/vv119#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
